(0.33%) 5 116.75 points
(0.32%) 38 363 points
(0.38%) 15 988 points
(-0.98%) $83.03
(5.51%) $2.03
(0.30%) $2 354.30
(0.42%) $27.65
(4.10%) $959.95
(-0.27%) $0.932
(-0.43%) $10.98
(-0.57%) $0.796
(1.66%) $93.40
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 12.97%
@ $10.44
発行日: 14 2月 2024 @ 00:07
リターン: 37.89%
前回のシグナル: 2月 13 - 03:04
前回のシグナル:
リターン: -6.09 %
Live Chart Being Loaded With Signals
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States...
Stats | |
---|---|
本日の出来高 | 1 905.00 |
平均出来高 | 32 898.00 |
時価総額 | 84.87M |
EPS | $0 ( 2024-02-08 ) |
次の収益日 | ( $-1.940 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.610 |
ATR14 | $0.108 (0.75%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-05-01 | Zung Jonathan B. | Buy | 500 000 | Employee stock option (right to buy) |
2023-05-01 | Zung Jonathan B. | Buy | 0 | |
2023-01-23 | Kaitin Kenneth I | Buy | 85 000 | Non Qualified Stock Option |
2023-01-23 | Hohneker John | Buy | 85 000 | Non Qualified Stock Option |
2023-01-23 | Rubin Marc | Buy | 85 000 | Non Qualified Stock Option |
INSIDER POWER |
---|
86.12 |
Last 97 transactions |
Buy: 14 857 117 | Sell: 1 304 959 |
Curis Inc 相関
10 最も負の相関 | |
---|---|
AMRB | -0.912 |
PKOH | -0.886 |
SMH | -0.881 |
SNCY | -0.873 |
GPRE | -0.85 |
VOXX | -0.846 |
VTRU | -0.833 |
PSCC | -0.831 |
PSEC | -0.828 |
HLNE | -0.828 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Curis Inc 財務諸表
Annual | 2023 |
収益: | $10.02M |
総利益: | $9.81M (97.88 %) |
EPS: | $-8.96 |
FY | 2023 |
収益: | $10.02M |
総利益: | $9.81M (97.88 %) |
EPS: | $-8.96 |
FY | 2022 |
収益: | $10.16M |
総利益: | $9.91M (97.47 %) |
EPS: | $-12.92 |
FY | 2021 |
収益: | $10.65M |
総利益: | $10.12M (94.99 %) |
EPS: | $-0.500 |
Financial Reports:
No articles found.
Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。